People: AEterna Zentaris Inc (AEZS.O)
20 Dec 2013
Mr. David A. Dodd is President, Chief Executive Officer, Director of Aeterna Zentaris Inc., with effect from April 15, 2013. Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From December 2007 to June 2009, Mr. Dodd was President, CEO and Chairman of BioReliance Corporation, a provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the Company to Stem Cells, Inc., in April 2009. During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation. Currently, he serves as Chair, Board of Directors, of GeoVax, Inc., a biotechnology company developing innovative, patented HIV/AIDS vaccines; as a Director on the Board of Aruna Biomedical, a privately-held life science development company focused on the development and commercialization of stem cell research products and services; and, as a Director on the Board of PNP Therapeutics, a clinical stage company, developing a novel nucleoside-booster treatment for solid tumor mass cancers. He also serves as CEO of RiversEdge BioVentures LLC ("RiversEdge"), which he founded in 2009. RiversEdge is an investment and advisory firm focused on the life sciences and pharmaceutical industry. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University, and completed the Harvard Business School of Advanced Management Program. His numerous public service activities include the American Foundation for Suicide Prevention, and the Board of Directors of the Institute of Bioengineering and Bioscience at Georgia Institute of Technology.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|